Atlantic Ocean's Nanoplastic Problem Revealed in Shocking New Study
Led by a team from Utrecht University in the Netherlands, the study is based on samples taken at varying depths from 12 sites across the North Atlantic. High-resolution imaging scans and chemical filtering were used to find nanoplastics in the samples, which can be tricky to spot due to their very small size (just a fraction of the thickness of a human hair).
The analysis was clear: the ocean is swimming with nanoplastics, perhaps some 27 million tonnes when extrapolated across the whole of the North Atlantic Ocean. That's almost a tenth of the entire volume of trash thrown away in the US each year.
"This estimate shows that there is more plastic in the form of nanoparticles floating in this part of the ocean than there is in larger micro or macroplastics floating in the Atlantic or even all the world's oceans," says biogeochemist Helge Niemann, from Utrecht University.
Related:
The findings illustrate the sheer scale of the ecological problem posed by waste plastics.
Polyethylene terephthalate (PET), polystyrene (PS), and polyvinyl chloride (PVC) plastics were all found, commonly used in plastic bottles, cups, and films.
Some plastics were largely missing though: polyethylene and polypropylene, which are ubiquitous in the environment. The researchers think this might be because organic particles are masking their presence, or the analysis techniques in use aren't currently sensitive enough to pick these types of plastic up.
Nanoplastics were found at all of the surveyed depths, but were particularly concentrated around the coasts (from rivers and runoff) and in the subtropical gyre, a place of swirling circular currents that's well known for trapping plastics which proceed to break up into ever-finer pieces.
What's not clear is the precise extent to which plastics harm marine ecosystems, and in turn species that rely upon them. Including our own. Super-small nanoplastics can interact with water, sediment, and other organisms in ways larger microplastics can't.
"Nanoplastic and nanoparticles are so small that the physical laws governing larger particles often no longer apply," says chemist Dušan Materić, from the Helmholtz Centre for Environmental Research in Germany.
Next, the researchers want to see more ocean areas sampled, with surveys scanned for more types of plastic – something that should be possible by adapting the techniques used in this study. It's also important to look for nanoplastics at different stages of degradation, based on how long they've been in the water.
Plastic pollution at this scale is going to be very difficult to eliminate, which is why the researchers are calling for more to be done to stop plastics from entering the environment in the first place.
"Only a couple of years ago, there was still debate over whether nanoplastic even exists," says Materić. "Many scholars continue to believe that nanoplastics are thermodynamically unlikely to persist in nature, as their formation requires high energy."
"Our findings show that, by mass, the amount of nanoplastic is comparable to what was previously found for macro and microplastic – at least in this ocean system."
The research has been published in Nature.
Scientists Discovered This Amazing Practical Use For Leftover Coffee Grounds
Antarctica's Ocean Is Mysteriously Getting Saltier, Spelling End to Sea Ice
Earth's Energy Imbalance Has Doubled in 2 Decades, Study Warns
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Topflight Pharma Development Veteran Joins Synendos
Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy Dr. George Garibaldi, MD BASEL, Switzerland, July 15, 2025 (GLOBE NEWSWIRE) -- Synendos Therapeutics ('Synendos'), the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced today that it has named Dr. George Garibaldi, CMO. This appointment is particularly timely as the company moves towards Phase 2 clinical development of its lead drug asset SYT-510. Synendos CEO, Andrea Chicca said, "It's tremendous that Synendos can attract this calibre of talent and experience. George offers a nuanced clinical perspective on the urgent needs of the patients we are looking to help, combined with specific expertise in advancing transformative neuroscience therapies from concept to clinical adoption.' Dr. George Garibaldi is a psychiatrist and neuroscientist with more than 30 years of experience leading global clinical development programs in CNS disorders. His career spans leadership roles at Roche, Novartis and Janssen, where he oversaw the development of breakthrough treatments including Ocrevus® for primary progressive and relapsing remitting multiple sclerosis and Exelon® for Alzheimer's disease and Lewi body dementia. As co-founder of Noema Pharma, he spearheaded the in-licensing and advancement of shelved CNS assets, securing major venture funding and progressing them through pivotal clinical trials. Known for his strong beliefs in empowering patients, Dr. Garibaldi has published more than 100 peer-reviewed articles and has developed widely used clinician- and patient-reported outcome measures. He is a founder and past president of the International Society for CNS Clinical Trials and Methodology and is recognized by peers as a collaborative, strategic leader dedicated to advancing mental health and neuroscience therapeutics. 'Mental health and brain health have for far too long been underserved by traditional drug development models,' said Dr. Garibaldi. "Synendos is combining the pursuit of an innovative target with a commitment to rethinking how we design trials, measure outcomes and prioritize patient function. It's this willingness to be ahead of the curve with therapeutic innovation and a genuine patient focus that made me want to be part of the company.' He added, 'Society today recognizes that there is no health without mental health. We have the rare opportunity to chart our own path here. I am eager to lead this transformation and help this exceptional team advance the next generation of brain therapies that could truly change the lives of patients.' About SynendosSynendos is a clinical-stage, neuroscience company developing potentially breakthrough therapies for neuropsychiatric and other CNS disorders such as anxiety disorders, PTSD and other indications. We utilise the modulation of a new drug target in the endocannabinoid system (ECS) that enables restoration of the natural functioning of the brain. Synendos' lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). SERIs represent first-in-class, new chemical entities that modulate the ECS through a self-limiting mode of action (MoA) with the potential to deliver meaningful benefits to patients. This novel MoA has the potential to combine treatment of a range of symptoms with sustained efficacy in large patient populations together with the potential to address a key unmet need, that of chronic tolerability, allowing more patients to stay on treatment and regain an improved quality of life. For more information please contact: Synendos Therapeutics AG Simon Russell +41 79 138 5840 O Public Relations GmbHO'Patrick Wilson o@ 78 888 4332 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Welsh Ambulance Service to lead study on emergency video consultation
Live video consultations could be used to help decision-making in response to 999 calls following a study being led ay the Welsh Ambulance Service. The 999 RESPOND-2 study is being funded by the National Institute for Health and Care Research and aims to improve decision-making around whether to send Enhanced Critical Care Teams to emergency calls. These teams deliver advanced care for seriously ill and injured patients at the scene of an incident. It is currently difficult for control room clinicians to fully capture the complexity and volume of information they need to make the best decision. Advances in technology have enabled ambulance services to test live-stream video from callers' smart phones during an emergency call, to help ambulance staff assess quickly and accurately how urgently help is needed for an unwell patient. Professor Nigel Rees, assistant director of research and innovation at the Welsh Ambulance Service, said: 'We're studying how emergency critical care teams size up risk and severity in high pressured and time sensitive situations. 'We are doing this by comparing video consultation calls, where clinicians can see the patient, the accident scene and other factors as opposed to traditional 999 calls, where the clinician can only make a decision based on descriptions from the caller. 'We hope to learn more about who sees what, who says what and how these decisions shape emergency response when seconds matter and really can be the difference between life and death. 'From major trauma to severe medical emergencies, ECCTs are integral to pre-hospital and emergency services, but they are a finite resource.' The study is the first to consider the impact of live-stream video in how people communicate with each other in 999 calls and to provide evidence on whether live-stream videos can overcome some limitations of audio 999 calls. It is a collaboration between clinicians and researchers across the Welsh Ambulance Service, West Midlands Ambulance Service, University of Warwick, University of Bristol, Imperial College London, Aberystwyth University, the Emergency Medical Retrieval and Transfer Service and the Wales Air Ambulance Charity.
Yahoo
7 hours ago
- Yahoo
Da Vinci's Vitruvian Man Encodes the Blueprint of Human Evolution, Says London Dentist
New research reveals a hidden geometric ratio in Leonardo's drawing that may define the endpoint of human evolution toward upright posturePhoto Courtesy of Rory Mac Sweeney LONDON, July 14, 2025 (GLOBE NEWSWIRE) -- A London-based dental surgeon and researcher, Dr. Rory Mac Sweeney of Precision Endodontics, has ignited international interest with a provocative reinterpretation of Leonardo da Vinci's Vitruvian Man. His newly published research suggests the Renaissance masterpiece encodes a precise geometric ratio that reflects the biomechanical endpoint of human evolution. Dr. Mac Sweeney's theory, published in the Journal of Mathematics and the Arts, identifies a hidden equilateral triangle embedded in Vitruvian Man. He connects this geometry to Bonwill's Triangle—a fundamental dental structure first described in the 19th century, which governs optimal jaw alignment and function. According to Mac Sweeney, this triangular structure appears throughout the body and is mathematically anchored by the ratio √8/3, or approximately 1.633. 'Leonardo's drawing isn't just a study in proportion—it's a map of tension,' said Dr. Mac Sweeney. 'The 1.633 ratio appears in the jaw, the spine, and the skull. It reflects a state known as vector equilibrium, where structural tension and compression are perfectly balanced. I believe this marks the final step in the human journey toward full upright posture.' This ratio, derived from the geometry of the cuboctahedron, is widely recognized in biomechanics and architecture as a hallmark of tensegrity—the balance of forces within a stable form. Dr. Mac Sweeney contends that this geometry defines the Vitruvian Morphotype: a form that nature has converged on through evolutionary pressures—not because it is aesthetically pleasing, but because it is structurally optimal. 'Human evolution has been a long progression toward uprightness,' he explained. 'The 1.633 ratio may represent our evolutionary omega point—a structural threshold beyond which no further anatomical adaptation is needed to stand, move, and balance efficiently in gravity.' Mac Sweeney suggests that fossil evidence should reveal a slow convergence toward this geometric configuration, particularly in the jaw. He highlights the emergence of Class I occlusion in the fossil record—also known as the overbite/overjet 'step'—around 8,000 years ago as a key moment. While small variations remain, he argues that modern Homo sapiens are the first species to fully express this morphotype. 'It's like the hydrodynamic form of a dolphin,' he said. 'Nature solves gravity the way it solves water. Vitruvian Man is the first full sketch of what that solution looks like.' Dr. Mac Sweeney's theory is now attracting attention from experts in evolutionary biology, bioengineering, and anatomical design. He is currently conducting interviews, public talks, and media appearances to discuss what he calls the Vitruvian Ratio—and its broader implications for anthropology, architecture, and even consciousness. 'Leonardo, somehow, saw it coming,' Mac Sweeney added. 'Vitruvian Man may be the only anatomical diagram ever created that captures not just what a human is—but what a human is becoming.' About Dr. Rory Mac Sweeney: Dr. Mac Sweeney is a London-based endodontist and researcher known for his interdisciplinary work in dental anatomy, geometry, and human evolution. His work explores the convergence of structural biology and classical design, and he is the author of the book The Paradox of Lucid Dreaming. @luciddreamyoga Contact Information: Contact person: Dr. Rory Mac SweeneyCompany name: Precision EndodonticsWebsite: [ Contact: rorymacsweeney@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data